Eric Singhi, Thoracic Medical Oncologist and Assistant Professor at MD Anderson Cancer Center, shared a post on LinkedIn:
“2025 was a year of progress in lung cancer.
New FDA approvals across NSCLC and SCLC translated into meaningful advances for our patients.
Each approval reflects years of science, clinical trial participation, and partnership with patients and their families.
We end 2025 encouraged, and look forward to even more innovation in 2026.”
More posts featuring Eric K. Singhi on OncoDaily.